DE3486474T2 - Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit - Google Patents
Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha UntereinheitInfo
- Publication number
- DE3486474T2 DE3486474T2 DE3486474T DE3486474T DE3486474T2 DE 3486474 T2 DE3486474 T2 DE 3486474T2 DE 3486474 T DE3486474 T DE 3486474T DE 3486474 T DE3486474 T DE 3486474T DE 3486474 T2 DE3486474 T2 DE 3486474T2
- Authority
- DE
- Germany
- Prior art keywords
- subunit
- vector
- promoter
- heterologous dna
- dna encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 108010073521 Luteinizing Hormone Proteins 0.000 claims abstract description 49
- 102000009151 Luteinizing Hormone Human genes 0.000 claims abstract description 49
- 229940040129 luteinizing hormone Drugs 0.000 claims abstract description 48
- 241000700605 Viruses Species 0.000 claims abstract description 27
- 239000013604 expression vector Substances 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 13
- 230000003362 replicative effect Effects 0.000 claims abstract description 13
- 108020004414 DNA Proteins 0.000 claims description 48
- 239000013598 vector Substances 0.000 claims description 31
- 241000588724 Escherichia coli Species 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 108090000157 Metallothionein Proteins 0.000 claims description 8
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 7
- 102000003792 Metallothionein Human genes 0.000 claims description 7
- 238000001890 transfection Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000004481 post-translational protein modification Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 241000701822 Bovine papillomavirus Species 0.000 claims 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 239000013612 plasmid Substances 0.000 abstract description 80
- 229940088597 hormone Drugs 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract 2
- 102000011923 Thyrotropin Human genes 0.000 abstract 2
- 108010061174 Thyrotropin Proteins 0.000 abstract 2
- 229940028334 follicle stimulating hormone Drugs 0.000 abstract 2
- 239000012634 fragment Substances 0.000 description 46
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 40
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 40
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 40
- 239000002299 complementary DNA Substances 0.000 description 32
- 238000010276 construction Methods 0.000 description 20
- 230000029087 digestion Effects 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 101710132601 Capsid protein Proteins 0.000 description 9
- 101710197658 Capsid protein VP1 Proteins 0.000 description 8
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 8
- 101710108545 Viral protein 1 Proteins 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 108020005202 Viral DNA Proteins 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003169 placental effect Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108020004638 Circular DNA Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 101710149086 Nuclease S1 Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 101710166678 50S ribosomal protein L28, chloroplastic Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101000832455 Pimpla hypochondriaca Small venom protein 1 Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- ULSFNUQXUHMWNZ-UHFFFAOYSA-N crl-8401 Chemical compound O=C1C2=NC=CC=C2C2=NC=CC3=C2C1=NC=C3OC ULSFNUQXUHMWNZ-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 102000055647 human CSF2RB Human genes 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100311330 Schizosaccharomyces pombe (strain 972 / ATCC 24843) uap56 gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108010000209 endodeoxyribonuclease HgaI Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 101150018444 sub2 gene Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54821183A | 1983-11-02 | 1983-11-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3486474D1 DE3486474D1 (de) | 2000-02-03 |
| DE3486474T2 true DE3486474T2 (de) | 2000-08-03 |
Family
ID=24187868
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3486474T Expired - Lifetime DE3486474T2 (de) | 1983-11-02 | 1984-10-31 | Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit |
| DE2001199028 Active DE10199028I2 (de) | 1983-11-02 | 1984-10-31 | Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit. |
| DE2001199035 Active DE10199035I2 (de) | 1983-11-02 | 1984-10-31 | Herstellung heterodimerer menschlicher Fruchtbarkeitshormone |
| DE3486469T Expired - Lifetime DE3486469T2 (de) | 1983-11-02 | 1984-10-31 | Herstellung heterodimirer menschlicher Fruchtbarkeitshormone |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2001199028 Active DE10199028I2 (de) | 1983-11-02 | 1984-10-31 | Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit. |
| DE2001199035 Active DE10199035I2 (de) | 1983-11-02 | 1984-10-31 | Herstellung heterodimerer menschlicher Fruchtbarkeitshormone |
| DE3486469T Expired - Lifetime DE3486469T2 (de) | 1983-11-02 | 1984-10-31 | Herstellung heterodimirer menschlicher Fruchtbarkeitshormone |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP0578328B1 (da) |
| AT (2) | ATE190461T1 (da) |
| DE (4) | DE3486474T2 (da) |
| DK (2) | DK297285D0 (da) |
| LU (1) | LU90770I2 (da) |
| MX (1) | MX9203334A (da) |
| NL (1) | NL300044I2 (da) |
| WO (1) | WO1985001959A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923805A (en) * | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| US5639639A (en) * | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
| JPS60145098A (ja) * | 1984-01-09 | 1985-07-31 | Suntory Ltd | 糖付加ポリペプチドの製造法 |
| EP0224574A4 (en) * | 1985-06-04 | 1988-04-26 | Biotech Res Partners Ltd | SELF-ANTIGEN VACCINES. |
| CA1340740C (en) * | 1987-12-08 | 1999-09-14 | Eileen R. Mulvihill | Co-expression in eukaryotic cells |
| US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| US5792460A (en) * | 1989-02-21 | 1998-08-11 | Washington University | Modified glycoprotein hormones having a CTP at the amino terminus |
| US6225449B1 (en) | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
| US5705478A (en) * | 1989-02-21 | 1998-01-06 | Washington University | Covalently linked β subunits of the glycoprotein hormones as antagonists |
| CA2053864C (en) * | 1989-02-21 | 2001-11-20 | Irving Boime | Modified forms of reproductive hormones |
| US6028177A (en) * | 1991-10-04 | 2000-02-22 | Washington University | Methods of detecting single-chain forms of the glycoprotein hormone quartet |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| US6737515B2 (en) | 1993-11-19 | 2004-05-18 | Washington University | Follicle stimulating hormone-glycosylation analogs |
| US6238890B1 (en) | 1994-02-18 | 2001-05-29 | Washington University | Single chain forms of the glycoprotein hormone quartet |
| BR9506313A (pt) * | 1994-08-12 | 1997-08-05 | Univ Washington | Formas de cadeia simples do quarteto de hormônio de glicoproteína |
| RU2213099C2 (ru) * | 1994-08-12 | 2003-09-27 | Вашингтон Юниверсити | Одноцепочечный белок, модулятор гормонов лютеинизирующего, фолликулостимулирующего, тиреостимулирующего и хорионического гонадотропина (варианты), молекула нуклеиновой кислоты (варианты), вектор (варианты), линия трансформированных клеток сно (варианты), способ продуцирования одноцепочечного белка (варианты) |
| DK0725795T3 (da) * | 1994-08-12 | 2004-05-17 | Univ Washington | Enkelt-kæde form af glycoprotein-hormon-kvartetten |
| US6635256B1 (en) | 1998-10-19 | 2003-10-21 | Washington University | Glycoprotein hormone compositions comprising two β subunits and methods of use thereof |
| US6103501A (en) * | 1997-11-17 | 2000-08-15 | Washington University | Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof |
| EP1013281A1 (en) | 1998-12-15 | 2000-06-28 | Applied Research Systems ARS Holding N.V. | hCG therapy for the treatment of breast cancer |
| US7112341B1 (en) | 1999-04-13 | 2006-09-26 | Nektar Therapeutics | Pulmonary administration of dry powder formulations for treating infertility |
| CA2466595A1 (en) * | 2001-11-08 | 2003-05-15 | William R. Moyle | Protein knobs |
| US7081446B2 (en) | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| WO2007030362A1 (en) | 2005-09-07 | 2007-03-15 | Laboratoires Serono Sa. | Ikk inhibitors for the treatment of endometriosis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2048894A (en) * | 1979-05-11 | 1980-12-17 | Gist Brocades Nv | Plasmid |
| US4419446A (en) * | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
-
1984
- 1984-10-31 AT AT93202294T patent/ATE190461T1/de active
- 1984-10-31 AT AT92200198T patent/ATE169334T1/de active
- 1984-10-31 DE DE3486474T patent/DE3486474T2/de not_active Expired - Lifetime
- 1984-10-31 EP EP93202294A patent/EP0578328B1/en not_active Expired - Lifetime
- 1984-10-31 MX MX9203334A patent/MX9203334A/es unknown
- 1984-10-31 WO PCT/US1984/001771 patent/WO1985001959A1/en not_active Ceased
- 1984-10-31 EP EP85900268A patent/EP0160699B1/en not_active Expired - Lifetime
- 1984-10-31 DE DE2001199028 patent/DE10199028I2/de active Active
- 1984-10-31 EP EP99107952A patent/EP0957167A1/en not_active Withdrawn
- 1984-10-31 DE DE2001199035 patent/DE10199035I2/de active Active
- 1984-10-31 DE DE3486469T patent/DE3486469T2/de not_active Expired - Lifetime
-
1985
- 1985-07-01 DK DK297285A patent/DK297285D0/da not_active Application Discontinuation
- 1985-07-01 DK DK297185A patent/DK171489B1/da not_active IP Right Cessation
-
2001
- 2001-05-03 LU LU90770C patent/LU90770I2/fr unknown
- 2001-05-10 NL NL300044C patent/NL300044I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE190461T1 (de) | 2000-04-15 |
| MX9203334A (es) | 1992-09-01 |
| LU90770I2 (fr) | 2001-07-03 |
| EP0160699A4 (en) | 1987-10-20 |
| DK297285A (da) | 1985-07-01 |
| ATE169334T1 (de) | 1998-08-15 |
| EP0160699B1 (en) | 1992-08-12 |
| NL300044I1 (nl) | 2001-07-02 |
| DE10199028I2 (de) | 2004-07-01 |
| DK297285D0 (da) | 1985-07-01 |
| DE10199028I1 (de) | 2001-09-20 |
| EP0160699A1 (en) | 1985-11-13 |
| DE3486474D1 (de) | 2000-02-03 |
| WO1985001959A1 (en) | 1985-05-09 |
| EP0578328B1 (en) | 1999-12-29 |
| DE10199035I1 (de) | 2001-11-08 |
| DK297185A (da) | 1985-07-01 |
| EP0957167A1 (en) | 1999-11-17 |
| NL300044I2 (nl) | 2001-12-01 |
| DK297185D0 (da) | 1985-07-01 |
| DE3486469D1 (de) | 1998-09-10 |
| DE10199035I2 (de) | 2006-03-16 |
| DK171489B1 (da) | 1996-11-25 |
| DE3486469T2 (de) | 1999-04-15 |
| EP0578328A1 (en) | 1994-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3486474T2 (de) | Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit | |
| DE3485869T2 (de) | Herstellung heterodimerer menschlicher fruchtbarkeitshormone. | |
| DE3688109T2 (de) | Fsh. | |
| DE3177288T3 (de) | Reife menschliche Leukozyten-Interferone, Verfahren zu ihrer bacteriellen Herstellung, Zwischenprodukte hierfür und Zusammensetzungen diese enthaltend. | |
| DE3588199T2 (de) | Lymphokin-Herstellung und -Reinigung | |
| DE3888379T2 (de) | Leukämie hemmender Faktor. | |
| DE3586335T2 (de) | Herstellung von gamma-interferon. | |
| DE3382575T2 (de) | Dna-sequenzen, rekombinante dna-molekuele und verfahren zur herstellung von schweinewachstumshormonaehnlichen polypeptiden. | |
| DE3851289T2 (de) | Verfahren zur Züchtung rekombinanter Zellen. | |
| DE3786767T3 (de) | Neues Polypeptid. | |
| US5639639A (en) | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof | |
| DE3650266T2 (de) | DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von "mullerian inhibiting substance"-ähnlichen Polypeptiden. | |
| DE3382789T2 (de) | Tierische Interferone, Verfahren bei deren Herstellung, dieselben enthaltende Zusammensetzungen, kodierende DNS-Sequenzen hierfür und diese Sequenzen enthaltende Expressionsvektoren und dadurch transformierte Zellen. | |
| CH656388A5 (de) | Dns-sequenzen und rekombinante expressionsvektoren zur mikrobiellen herstellung von human-fibroblasten-interferon. | |
| DE68915165T2 (de) | Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3. | |
| EP0099084A2 (de) | Verfahren zur Herstellung von Interferon und Expressionsvektoren dafür | |
| DE69329031T2 (de) | Das dorsalgewebe beeinflussender faktor | |
| DE69314574T2 (de) | Megakaryozyten-Differenzierungsfaktor | |
| DE3687141T2 (de) | Verfahren zur herstellung von peptiden. | |
| DE69231676T2 (de) | Methoden zur selektion von rekombinanten wirtszellen welche hohe mengen von einem gewünschten protein exprimieren | |
| DE69027948T2 (de) | Reinigung von rekombinantem, menschlichem Interleukin-3 | |
| DE68927104T2 (de) | Gentherapie unter verwendung von genschmelzen für genetische und erworbene störungen | |
| DE69233612T2 (de) | Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz | |
| DE3586830T2 (de) | Verfahren zur ligation von heterogenen genen. | |
| DE3750348T2 (de) | Verfahren zur Herstellung von Peptiden, dazu zu verwendendes rekombinantes Plasmid und mit diesem Plasmid transformierte Myelomzellen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| V448 | Application of spc |
Free format text: PRODUCT NAME: LUTROPIN ALFA (REKOMBINANTES HUMANES LUTEINISIERENDES HORMON (LH)); REGISTRATION NO/DATE: EU/1/00/155/001 - EU/1/00/155/006; 20001129 Spc suppl protection certif: 101 99 028 Filing date: 20010518 |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: GROSSE, BOCKHORNI, SCHUMACHER, 81476 MUENCHEN |
|
| V457 | Spc granted |
Free format text: PRODUCT NAME: LUTROPIN ALFA (REKOMBINANTES HUMANES LUTEINISIERENDES HORMON (LH)); REGISTRATION NO/DATE: EU/1/00/155/001 - EU/1/00/155/006; 20001129 Spc suppl protection certif: 101 99 028 Filing date: 20010518 |
|
| V464 | Spc expired |
Free format text: PRODUCT NAME: LUTROPIN ALFA (REKOMBINANTES HUMANES LUTEINISIERENDES HORMON (LH)); REGISTRATION NO/DATE: EU/1/00/155/001 - EU/1/00/155/006; 20001129 Spc suppl protection certif: 101 99 028 Filing date: 20010518 |